E-Learning Center
Join Our Network
OncoFacts

QUICK POLL

If imatinib, nilotinib, and dasatinib are all approved for front-line therapy of newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML), what would you recommend as front-line therapy for a 42-year-old man who presents with high-risk CML by both the Sokal and Hasford (Euro) scoring systems and who has no matched sibling donor?






Follow Imedex on Twitter

advances in ibd


Register Now

2009 Advances in Inflammatory Bowel Diseases Crohn’s & Colitis Foundation’s Clinical & Research Conference

December 3-6, 2009

Hollywood, Florida

The Westin Diplomat

Information coming soon.

 

Information coming soon.

.

.

 

Information coming soon.

 

Information coming soon.

Information coming soon.

Information coming soon.

Information coming soon.

Chairs:

Richard P. MacDermott, MD
Albany Medical College
Albany, New York

Stephen B. Hanauer, MD
University of Chicago
Chicago, Illinois

 

ORGANIZER

Imedex
4325 Alexander Drive
Alpharetta, GA 30022-3740 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

PDF Announcement

Information coming soon.

 

 

 

 

 

Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.

Information coming soon.